Nab-paclitaxel with gemcitabine [NAB2]

The treatment of untreated metastatic pancreatic cancer only if other combination chemotherapies are unsuitable and they would otherwise have gemcitabine monotherapy

  1. This application is being been made by and the first cycle of systemic anti-cancer therapy with nab-paclitaxel plus gemcitabine will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
  2. The patient has confirmed histological or cytological diagnosis of pancreatic adenocarcinoma.
  3. The patient has metastatic disease (patients with locally advanced disease are ineligible).
  4. The patient is either completely treatment naïve for systemic therapy for pancreatic cancer or the patient has received prior systemic anti-cancer therapy as neo-adjuvant or adjuvant therapy AND such treatment was completed at least 6 months previously. Please mark below whether or not previous systemic anti-cancer therapy for pancreatic cancer has ever been received in the neoadjuvant or the adjuvant disease settings:
  • no previous neoadjuvant/adjuvant systemic therapy of any kind and treatment naïve for metastatic pancreatic cancer
  • prior neoadjuvant chemotherapy for non-metastatic disease and the last dose received by the patient was 6 or more months prior to this application
  • prior chemotherapy in the adjuvant setting and the last dose received by the patient was 6 or more months prior to this application
  1. Nab-paclitaxel is to be used only in combination with gemcitabine. st
  2. Nab-paclitaxel plus gemcitabine is to be used as 1 line treatment only.
  3. The patient has a performance status of 0 or 1.
  4. The patient is not considered to be a suitable candidate for oxaliplatin- and irinotecan-based combination chemotherapy and would otherwise receive gemcitabine monotherapy.
  5. Nab-paclitaxel will otherwise be used as set out in its Summary of Product Characteristics (SPC).

[NHS funded]{.badge .rounded-pill .bg-success} From: 05 December 2017

Form version:

CDF Managed Access: NA

NICE Technology Appraisal: TA476 (06 September 2017)

Current Form Version

Important

This is an older version of the form. To view the most up to date form follow this link

Older Form Versions

There are previous versions of this form. These may not all be available on this site.